Premium
Body mass index and noninfectious comorbidity in HIV‐positive patients commencing antiretroviral therapy in Zimbabwe
Author(s) -
Bleasel JM,
Heron JE,
Shamu T,
Chimbetete C,
Dahwa R,
Gracey DM
Publication year - 2020
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12934
Subject(s) - medicine , body mass index , overweight , cohort , obesity , renal function , comorbidity , univariate analysis , retrospective cohort study , cohort study , multivariate analysis
Objectives The aim of the study was to describe the prevalence of elevated body mass index (BMI) in a cohort of treatment‐naïve people living with HIV (PLWH) and to investigate the association of BMI with CD4 count and noninfectious comorbidities including hypertension and renal impairment. Methods A retrospective cohort study of 1598 PLWH at the Newlands Clinic in Harare, Zimbabwe was carried out. Data were extracted from the medical records at baseline and 6 months after initiation of treatment. The univariate association between BMI and CD4 count was assessed and multiple regression models were used to predict factors associated with loss of renal function and change in CD4 count at 6 months. Results Overweight and obesity (BMI ≥ 25 kg/m 2 ) were prevalent in this cohort (34%), as was the presence of hypertension (18%). Higher BMI was associated with a higher CD4 count at baseline and 6 months ( B = 0.28 and 0.24, respectively; P < 0.001 for both), adjusted for age and sex. The presence of hypertension independently predicted loss of renal function at 6 months ( B = −15.31; P < 0.001), adjusted for BMI, CD4 count and sex. High BMI itself was also independently associated with a decline in renal function ( B = −0.41; P = 0.003), adjusted for other significant variables. Conclusions We demonstrate a high prevalence of overweight/obesity and hypertension in an urban cohort of PLWH in Zimbabwe. Higher BMI was associated with a higher CD4 count, both before and 6 months after commencing antiretroviral therapy; it was also associated with loss of renal function in this cohort.